Stockysis

Article

Stifel Downgrades Aardvark Therapeutics to Hold, Lowers Price Target to $6

Benzinga Newsdesk | Mar 02, 2026 11:05 | Source: www.benzinga.com

Stifel analyst James Condulis downgrades Aardvark Therapeutics (NASDAQ:AARD) from Buy to Hold and lowers the price target from $24 to $6.

Comments